Genzyme Financial Recovery Continues in Fourth Quarter
- Details
- Category: Genzyme
Genzyme Corp. (NASDAQ: GENZ) reported that preliminary fourth-quarter revenue grew 23 percent to $1.15 billion from $938 million in the fourth quarter of 2009. For the year, revenue was $4.1 billion compared with $4.0 billion in 2009.
Shire Reports Positive Signal Finding Study of Investigative Use of Vyvanse®
- Details
- Category: Shire
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced results from a study of Vyvanse® (lisdexamfetamine dimesylate), assessing its effect in a model for Excessive Daytime Sleepiness (EDS).
Abbott Receives CE Mark Approval for World's First Drug Eluting Bioresorbable Vascular Scaffold
- Details
- Category: Abbott
Abbott (NYSE: ABT) has received CE Mark approval for the world's first drug eluting bioresorbable vascular scaffold (BVS) for the treatment of coronary artery disease. Abbott's BVS device restores blood flow by opening a clogged vessel and providing support to the vessel until the device dissolves within approximately two years,
Genzyme Statement on Discussions With Sanofi-Aventis
- Details
- Category: Genzyme
Genzyme Corp. (NASDAQ: GENZ) reported today that discussions between its financial advisors and financial advisors for Sanofi-Aventis are continuing and have expanded to include representatives of both companies.
US Food and Drug Administration extend review timeline for vandetanib
- Details
- Category: AstraZeneca
AstraZeneca announced that the US Food and Drug Administration (FDA) has extended the time to complete its review of the New Drug Application (NDA) for the investigational drug vandetanib.
KOMBIGLYZE™ XR Now Available in U.S. Pharmacies
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY), and AstraZeneca (NYSE: AZN) announced that KOMBIGLYZE™ XR (saxagliptin and metformin HCl extended-release), approved by the U.S. Food and Drug Administration (FDA) on November 5, 2010, is now available by prescription in pharmacies across the United States.
FDA grants supplemental approval for ACTEMRA
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the United States (U.S.) Food and Drug Administration (FDA) has extended the ACTEMRA (tocilizumab, RoACTEMRA in the European Union) label to include inhibition and slowing of structural joint damage, improvement of physical function,
More Pharma News ...
- Amgen and Xencor Enter Option Deal to Co-Develop Xencor's Novel Antibody for Autoimmune Diseases
- Daxas® (Roflumilast) included as a new treatment option in latest international COPD guidelines
- Merck KGaA Acquires Supplier to Biopharma Industry in China
- GSK responds to 60 Minutes | Related Video
- First two clinical phase III studies confirm the profile of nalmefene
- European Commission approves Tasigna® for treatment of patients with newly diagnosed Ph+ chronic myeloid leukemia
- Sanofi-aventis Acquires from Ascendis Pharma Worldwide Rights on Drug-Delivery Technology